Application of eriodictyol in preparation of medicine for preventing and treating atherosclerosis
By using sago phenol or its pharmaceutically acceptable salts, the formation of lipid droplets and cholesterol levels are inhibited, and the signaling pathways are regulated, and the prevention and treatment problems of atherosclerosis are solved, and the treatment effect is achieved is achieved, which is better than existing drugs. .
Patent Information
- Application Number
- CN202410940769.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
AI Technical Summary
There is a lack of effective drugs in the prior art for the prevention and treatment of atherosclerosis, and the application of saccharomycete in this field has not been reported.
Using saccharophorol or its pharmaceutically acceptable salts, it can inhibit lipid droplet formation, intracellular lipid aggregation, reduce cholesterol levels, inhibit inflammatory responses in foam cells, and regulate PPARγ/ABCA1 and NF-κB signals by regulating PPARγ/ABCA1 and NF-κB signals. Access relief from atherosclerosis.
It significantly inhibits the occurrence of atherosclerosis, reduces the proportion of aortic root plaques to the lumen, regulates cholesterol aggregation, is better than reported catechins, and verifies its prevention and treatment effect in animal experiments.
Smart Images

Figure CN118903100A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine and relates to the application of eriodictyol in preparing a drug for preventing and treating atherosclerosis. Background Art
[0002] Atherosclerosis (AS) is a chronic vascular disease that mainly affects large and medium-sized arteries. The main clinical feature is chronic luminal stenosis. It is the main pathological basis of cardiovascular and cerebrovascular diseases such as coronary heart disease, cerebral infarction, and peripheral vascular disease. It affects the arterial system of the heart, brain, kidneys, eyes, and peripheral blood vessels. Atherosclerosis is associated with a variety of risk factors, such as hypercholesterolemia, hypertension, diabetes, obesity, high triglycerides, genetic abnormalities, and lifestyles including stress, lack of exercise, and smoking, which may cause damage to the inner layer of the arteries, leading to the development of atherosclerosis.
[0003] Eriodictyol is a polyphenolic flavonoid compound and a major precursor for the synthesis of downstream flavanols with high added value applications, such as quercetin and catechins. Eriodictyol is mainly found in citrus fruits and peanuts and is widely used in the pharmaceutical industry as an antioxidant, diet pill, and anti-Alzheimer's drug. Eriodictyol can also be directly applied to food as a food additive. There are no studies reporting the use of eriodictyol for the prevention and treatment of atherosclerosis. Summary of the invention
[0004] The purpose of the present invention is to provide the use of eriodictyol in preparing a drug for preventing and treating atherosclerosis.
[0005] In one aspect, the present invention relates to the use of eriodictyol or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing atherosclerosis.
[0006] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a drug to inhibit the formation of lipid droplets.
[0007] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a drug to inhibit intracellular lipid aggregation.
[0008] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a drug to reduce at least one of serum total cholesterol, free cholesterol, cholesterol ester and cholesterol ester / serum total cholesterol.
[0009] On the other hand, the present invention relates to the use of eriodictyol or a pharmaceutically acceptable salt thereof in preparing a drug for treating atherosclerosis.
[0010] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a drug to reduce the proportion of aortic root plaque in the lumen.
[0011] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a medicine to reduce the level of cholesterol ester and / or serum total cholesterol.
[0012] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a medicine to inhibit the inflammatory response of foam cells.
[0013] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a drug to alleviate atherosclerosis by regulating PPARγ / ABCA1 and / or NF-κB signaling pathways.
[0014] Furthermore, in the application provided by the present invention, eriodictyol or a pharmaceutically acceptable salt thereof is prepared into a drug for regulating cholesterol aggregation.
[0015] As used herein, the term "pharmaceutically acceptable" means having no long-term detrimental effect on the general health of the subject being treated.
[0016] In the present invention, the term "pharmaceutically acceptable salt" refers to a salt that retains the biological efficacy of eriodictyol and has no adverse effects in biology or other aspects. Pharmaceutically acceptable salts refer to the form of a base group in a parent compound converted into a salt, such as an inorganic or organic acid salt of a base group (such as an amine group), which is generally prepared by reacting the parent compound with a conventional type of acid in a solvent system. Inorganic acids generally include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, etc.; organic acids generally include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid or salicylic acid, etc.
[0017] As a preferred embodiment of pharmacy, those skilled in the art usually process the biologically active compound or its pharmaceutically acceptable salt with a pharmaceutically acceptable carrier into a drug for use. In order to use the eriodictyol or its pharmaceutically acceptable salt described in the present invention for the preparation of anti-kidney injury drugs, pharmaceutically acceptable formulations include capsules, tablets, powders or granules, etc. Those skilled in the art should know that the components of this drug, in addition to containing eriodictyol or its pharmaceutical, also include pharmaceutically acceptable carriers or adjuvants, such as olive oil, corn starch, citric acid, stearic acid, ethylene glycol, lactose, gypsum powder, magnesium stearate, ascorbic acid, gelatin, agar, etc.
[0018] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages.
[0019] The present invention verifies that eriodictyol can significantly inhibit the formation of lipid droplets induced by ox-LDL, regulate the intracellular cholesterol content, and inhibit the inflammatory response of foam cells caused by ox-LDL by intervening before or after ox-LDL stimulation through a cell model of foaming differentiated THP-1 cells stimulated by ox-LDL, and the mechanism of action is to regulate the PPARγ / ABCA1 and NF-κB signaling pathways to mediate the reduction of cholesterol efflux, lipid accumulation, and inflammatory response of foam cells induced by ox-LDL. The present invention also further verifies that eriodictyol can inhibit atherosclerosis, regulate cholesterol aggregation, and reduce the proportion of plaques in the aorta root of atherosclerotic mice in the lumen through animal experiments. The present invention compares the reported (+) catechins, and the preventive and therapeutic effect of eriodictyol on atherosclerosis is significantly higher than that of (+) catechins, and the preventive and therapeutic effect of eriodictyol is significantly reduced after being combined with (+) catechins in equal amounts. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the technical solution of the present invention, the drawings involved in the description of the embodiments will be briefly introduced below. Obviously, the drawings in the description are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1 Oil Red O staining of differentiated THP-1 cells stimulated by ox-LDL.
[0022] Figure 2 This is the Oil Red O staining of differentiated THP-1 cells stimulated by ox-LDL after intervention with eriodictyol extraction.
[0023] Figure 3 Oil Red O staining of differentiated THP-1 cells stimulated by ox-LDL after intervention with (+) catechin extraction.
[0024] Figure 4 It is a bar graph of OD values under different drug treatments.
[0025] Figure 5 This is a bar graph showing the effect of eriodictyol on the intracellular cholesterol content induced by ox-LDL.
[0026] Figure 6 It is a bar graph showing the regulatory effects of eriodictyol and its combination on CE / TC under different treatments.
[0027] Figure 7 This is a bar graph showing the effect of eriodictyol on inflammatory indicators of foam cells.
[0028] Figure 8This is a bar graph showing the effects of eriodictyol on the expression of ABCA1, PPARγ, p65, and p-p65 proteins.
[0029] Fig. 9 This is a bar graph showing the percentage of plaque in the aortic root lumen of AS mice under the intervention of eriodictyol.
[0030] Fig.10 This is a bar graph showing the changes in TG and TC indicators of AS mice under the intervention of eriodictyol.
[0031] In the above figure, # indicates P < 0.05 compared with the blank group, * indicates P < 0.05 compared with the model group, and a indicates P < 0.05 compared with the catechin group. DETAILED DESCRIPTION
[0032] The technical scheme of the present invention is described below in conjunction with the examples, but the present invention is not limited to the following examples. The experimental methods and detection methods described in each example are conventional methods unless otherwise specified; the reagents and materials are commercially available unless otherwise specified. The "%" indicates mass percentage unless otherwise specified.
[0033] The eriodictyol used in the following examples was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (≥98%, LOT: J15HB188611), and (+) catechin was purchased from Shanghai Yuanye Biotechnology Co., Ltd. (≥98%, LOT: S01HB191501).
[0034] Example 1
[0035] This example provides an experiment on the effect of eriodictyol in a cell model in which ox-LDL stimulates differentiated THP-1 cells to induce foaming.
[0036] The THP-1 cell line is an acute monocytic leukemia cell line and is an ideal tool for studying immunity and inflammation. THP-1 cells can be induced to differentiate into macrophages by phorbol myristate ester (PMA), and can induce M1 polarization through lipopolysaccharide (LPS) and IFN-γ, induce M2 polarization through IL-4 & IL-13 and macrophage colony stimulating factor (M-CSF), and release corresponding cytokines. Under the action of oxidized low-density lipoprotein (ox-LDL), macrophages can further form foam cells, which are characteristic pathological cells that appear in atherosclerotic plaques and are a chronic inflammatory model of atherosclerosis.
[0037] THP-1 cells were co-cultured with 100 nM PMA for 48 h to differentiate into macrophages, and then the culture medium was replaced with RPMI1640 (containing 0.5% fetal bovine serum) for 6 h of starvation culture. Cells were intervened with eriodictyol or (+) catechins (10 μmol / L) for 48 h in advance, and ox-LDL was used to treat cells for 48 h to induce foaming. After the intervention, Oil Red O staining was observed and the staining intensity was detected. Figure 1 and Figure 4 As shown in the figure, there are a large number of red lipid droplets in the differentiated THP-1 cells stimulated by ox-LDL, which is significantly different from the blank group (P<0.05). Figure 2 , Figure 3 and Figure 4 It can be seen that both eriodictyol and (+) catechins significantly inhibited the formation of lipid droplets induced by ox-LDL (P < 0.05); the effect of eriodictyol was better than that of (+) catechins, and the OD value decreased by 45.38% compared with the model group.
[0038] The effects of eriodictyol on the changes in intracellular TC (serum total cholesterol), FC (free cholesterol) and CE (cholesterol ester) levels induced by ox-LDL were further examined. Figure 5 As shown in the figure, compared with the blank group, the levels of TC and FC in the model group were significantly increased (P < 0.05), and CE and CE / TC were also significantly increased (P < 0.05). After intervention with eriodictyol, TC, FC, CE and CE / TC were significantly reduced (P < 0.05), indicating that eriodictyol regulates the accumulation of cholesterol in cells, thereby affecting lipid aggregation.
[0039] Further experiments were conducted to investigate the changes in intracellular TC and FC levels after intervention in foam cell models with combinations of eriodictyol and (+) catechins. Figure 6 As shown in the figure, compared with the blank group, the levels of TC and FC in the model group were significantly increased (P < 0.05), and CE / TC was also significantly increased (P < 0.05). The intervention of eriodictyol and its combination reduced CE / TC to varying degrees, but eriodictyol had the best effect (P < 0.05). The effect of eriodictyol combined with other components was reduced.
[0040] Elisa method was used to detect the contents of IL-6 and TNF-α and evaluate the effect of eriodictyol on the inflammatory response of foam cells. Figure 7 As shown in the figure, compared with the blank group, the secretion levels of IL-6 and TNF-α in the model group were significantly increased (P<0.05), that is, ox-LDL stimulation caused the inflammatory response of foam cells. The early intervention with eriodictyol significantly decreased the levels of IL-6 and TNF-α (P<0.05), indicating that eriodictyol can inhibit the inflammatory response caused by ox-LDL.
[0041] Western Blot was used to detect the expression of PPARγ and ABCA1 proteins, as well as the phosphorylation of p65, a key protein in the NF-κB signaling pathway. Figure 8 As shown in the figure, compared with the blank group, the expression levels of PPARγ and ABCA1 proteins in the model group were significantly increased (P<0.05). Compared with the model group, the intervention of eriodictyol further increased the expression levels of PPARγ and ABCA1 proteins (P<0.05). Ox-LDL induced THP-1 to form foam cells, which caused the increase of PPARγ and ABCA1 protein expression. Drug intervention further increased the expression levels of PPARγ and ABCA1 proteins, and the effects of drugs on cholesterol content and lipid aggregation were eliminated after inhibiting gene expression. Therefore, the activation of PPARγ / ABCA1 signaling pathway may be one of the ways for eriodictyol to affect cholesterol and lipid aggregation. In addition, compared with the blank group, the expression level of p-p65 protein in the model group was significantly increased (P<0.05). Early intervention of eriodictyol significantly reduced the phosphorylation level of p65 (P<0.05), indicating that eriodictyol reduced the inflammatory response by inhibiting the NF-κB signaling pathway. In conclusion, eriodictyol mediates the reduction of ox-LDL-induced cholesterol efflux, lipid accumulation, and inflammatory response in foam cells by regulating PPARγ / ABCA1 and NF-κB signaling pathways.
[0042] Example 2
[0043] This example provides an experiment on the effect of eriodictyol on AS in mice.
[0044] C57BL / 6J mice were fed a normal diet as a blank group, and ApoE- / - mice were fed a high-fat diet to establish the model. They were randomly divided into: model group, eriodictyol group (100 mg·kg -1 ·d -1 The blank group and the model group were given equal volumes of saline for 8 consecutive weeks. After the experiment, the aortic root sections were sliced and stained with HE, and the plaques were observed under a microscope. The model group and the eriodictyol group were quantitatively counted. Fig. 9 As shown in the figure, the proportion of plaques in the aortic root of mice in the eriodictyol group was significantly reduced (P<0.05). At the same time, the levels of TG and TC in the serum of mice were detected. The results showed that compared with the blank group, the levels of TG and TC in the model group were significantly increased (P<0.05). Fig.10 As shown, intervention with eriodictyol significantly reduced the levels of TG and TC (P < 0.05), indicating that eriodictyol can inhibit AS in mice and regulate cholesterol aggregation.
[0045] The embodiments described above are part of the embodiments of the present invention, but not all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but only represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the concept of the present invention belong to the scope of protection of the present invention.
Claims
1. Use of eriodictyol or a pharmaceutically acceptable salt thereof in the preparation of a drug for preventing atherosclerosis.
2. The use according to claim 1, It is characterized in that The drug inhibits lipid droplet formation.
3. The use according to claim 1, It is characterized in that The drug inhibits intracellular lipid aggregation.
4. The use according to claim 1, It is characterized in that The drug reduces at least one of the indicators of serum total cholesterol, free cholesterol, cholesterol ester and cholesterol ester / serum total cholesterol.
5. Use of eriodictyol or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating atherosclerosis.
6. The use according to claim 5, It is characterized in that The drug reduces the proportion of plaque to lumen in the aortic root.
7. The use according to claim 5, It is characterized in that The medicament reduces the level of cholesteryl esters and / or total serum cholesterol.
8. The use according to claim 5, It is characterized in that The drug inhibits the inflammatory response of foam cells.
9. The use according to claim 5, It is characterized in that The drug alleviates atherosclerosis by regulating PPARγ / ABCA1 and / or NF-κB signaling pathways.
10. The use according to claim 5, It is characterized in that The drug modulates cholesterol aggregation.
